SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
________________
Date of Report (Date of earliest event reported):
October 9, 1995
ALPHARMA INC.
(Exact name of registrant as specified in its charter)
Delaware 1-8593 22-2095212
________ ______ __________
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) No.)
One Executive Drive, Fort Lee, New Jersey 07024
___________________________________________________
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code
(201) 947-7774
A.L. Pharma Inc.
________________________________________________
(Former name or former address, if changed since
last report)
Item 5. Other Events
On October 9, 1995, the registrant issued the Press Release
attached as an Exhibit to this report.
Item 7. Financial Statements and Exhibits
(c) Exhibits
28. Press Release Dated October 9, 1995
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the Registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly
authorized.
ALPHARMA INC.
_________________
Registrant
By: /s/ Jeffrey E. Smith
___________________________
Jeffrey E. Smith
Vice President, Finance and
Chief Financial Officer
Dated: October 16, 1995
ALPHARMA LISTS WARRANTS FOR TRADING ON
NEW YORK STOCK EXCHANGE
Fort Lee, NJ, October 9, 1995 - ALPHARMA INC. (NYSE:ALO)
announced that effective today, Warrants to purchase
approximately 2.45 million shares of the Company's Class A Common
Stock have been listed for trading on the New York Stock
Exchange. The Warrants have an exercise price of $2l.945 and
are exercisable at any time prior to their expiration on January
3, 1999. On Friday, October 6, 1995, the closing price of the
Company's common stock on the NYSE was $23.00.
These Warrants were issued to the shareholders of the
Norwegian pharmaceutical company, Apothekernes Laboratorium A.S,
in October 1994 as part of the consideration paid by ALPHARMA in
connection with the transaction which combined the human
pharmaceutical animal health businesses of that company with
ALPHARMA. The closing price of the Company's common stock
at the October 3, 1994 issuance of the Warrants was
$17.13. Warrants to purchase a total of 3.6 million shares
were issued at that time. However, by agreement, Warrants to
purchase 2.45 million shares are being listed for trading now,
with the balance of the Warrants to purchase approximately 1.15
million shares to be listed for trading in October 1997.
The Company currently has 21.6 million shares of its common
stock outstanding. If all the Warrants issued are exercised
before their January 1999 expiration date, 3.6 million additional
shares will be issued with ALPHARMA receiving proceeds of
approximately $79 million.
ALPHARMA is a multinational pharmaceutical company
developing, manufacturing and marketing specialty generic and
proprietary human pharmaceutical and animal health products.
ALPHARMA is the largest manufacturer of generic liquid and
topical pharmaceuticals in the U.S., has an established and
growing market position in finished pharmaceuticals in Europe and
the Far East, is a basic manufacturer of important specialty
antibiotics, and is recognized worldwide as a leading provider of
animal health feed additives for poultry and livestock, and
vaccines for farmed fish.
